134 related articles for article (PubMed ID: 28546502)
1. Can we design a better anti-cytokine therapy?
Drutskaya MS; Efimov GA; Kruglov AA; Nedospasov SA
J Leukoc Biol; 2017 Sep; 102(3):783-790. PubMed ID: 28546502
[TBL] [Abstract][Full Text] [Related]
2. Making anti-cytokine therapy more selective: Studies in mice.
Drutskaya MS; Efimov GA; Astrakhantseva IV; Kruglov AA; Nedospasov SA
Cytokine; 2018 Jan; 101():33-38. PubMed ID: 27624866
[TBL] [Abstract][Full Text] [Related]
3. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice.
Winsauer C; Kruglov AA; Chashchina AA; Drutskaya MS; Nedospasov SA
Cytokine Growth Factor Rev; 2014 Apr; 25(2):115-23. PubMed ID: 24405806
[TBL] [Abstract][Full Text] [Related]
4. [Cytokine neutralization at specific cellular source : A new therapeutic paradigm? German Version].
Kruglov AA; Nedospasov SA
Z Rheumatol; 2017 Mar; 76(2):163-165. PubMed ID: 28058501
[TBL] [Abstract][Full Text] [Related]
5. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
6. [Interleukin-6 From molecular mechanisms of signal transduction to physiological properties and therapeutic targeting].
Drutskaya MS; Nosenko MA; Atretkhany KS; Efimov GA; Nedospasov SA
Mol Biol (Mosk); 2015; 49(6):937-43. PubMed ID: 26710772
[TBL] [Abstract][Full Text] [Related]
7. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Fleischer V; Sieber J; Fleischer SJ; Shock A; Heine G; Daridon C; Dörner T
Arthritis Res Ther; 2015 Jul; 17(1):185. PubMed ID: 26183319
[TBL] [Abstract][Full Text] [Related]
8. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
Ho LJ; Luo SF; Lai JH
Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
[TBL] [Abstract][Full Text] [Related]
9. Anti-cytokine antibodies for rheumatic diseases.
Atzeni F; Sarzi-Puttini P
Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
[TBL] [Abstract][Full Text] [Related]
10. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics.
Jang DI; Lee AH; Shin HY; Song HR; Park JH; Kang TB; Lee SR; Yang SH
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800290
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
12. Cytokine signal regulation and autoimmune disorders.
Nishimoto N
Autoimmunity; 2005 Aug; 38(5):359-67. PubMed ID: 16227151
[TBL] [Abstract][Full Text] [Related]
13. Perspective of cytokine regulation for periodontal treatment: fibroblast biology.
Takashiba S; Naruishi K; Murayama Y
J Periodontol; 2003 Jan; 74(1):103-10. PubMed ID: 12593604
[TBL] [Abstract][Full Text] [Related]
14. Modern anti-cytokine therapy of autoimmune diseases.
Astrakhantseva IV; Efimov GA; Drutskaya MS; Kruglov AA; Nedospasov SA
Biochemistry (Mosc); 2014 Dec; 79(12):1308-21. PubMed ID: 25716724
[TBL] [Abstract][Full Text] [Related]
15. Cytokine inhibition as a strategy for treating systemic lupus erythematosus.
Clark DN; Markham JL; Sloan CS; Poole BD
Clin Immunol; 2013 Sep; 148(3):335-43. PubMed ID: 23200699
[TBL] [Abstract][Full Text] [Related]
16. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
17. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages.
Yasukawa H; Ohishi M; Mori H; Murakami M; Chinen T; Aki D; Hanada T; Takeda K; Akira S; Hoshijima M; Hirano T; Chien KR; Yoshimura A
Nat Immunol; 2003 Jun; 4(6):551-6. PubMed ID: 12754507
[TBL] [Abstract][Full Text] [Related]
18. IL-6 signal transduction and its physiological roles: the signal orchestration model.
Kamimura D; Ishihara K; Hirano T
Rev Physiol Biochem Pharmacol; 2003; 149():1-38. PubMed ID: 12687404
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 as a therapeutic target in candidate inflammatory diseases.
Nishimoto N
Clin Pharmacol Ther; 2010 Apr; 87(4):483-7. PubMed ID: 20182422
[TBL] [Abstract][Full Text] [Related]
20. Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6.
Sharma S; Gupta S; Khajuria V; Bhagat A; Ahmed Z; Shah BA
Bioorg Med Chem Lett; 2016 Jan; 26(2):695-698. PubMed ID: 26711891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
